Longwood Capital Partners
Latest statistics and disclosures from Acuta Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are OCUL, CDTX, TRML, WHWK, INSM, and represent 53.79% of Acuta Capital Partners's stock portfolio.
- Added to shares of these 10 stocks: AMLX, CMPX, DRUG, KRYS, OCUL, COGT, DNTH, UTHR, INBX, Lb Pharmaceuticals.
- Started 8 new stock positions in UTHR, COGT, Lb Pharmaceuticals, DNTH, INBX, CMPX, AMLX, KRYS.
- Reduced shares in these 10 stocks: SLNO (-$5.3M), CDTX, TRVI, ASND, RVMD, HLXB, PRAX, AKRO, LQDA, RARE.
- Sold out of its positions in AKRO, ARTV, LQDA, RAPP, SLNO, TRVI, RARE, HLXB.
- Acuta Capital Partners was a net seller of stock by $-5.9M.
- Acuta Capital Partners has $97M in assets under management (AUM), dropping by 35.08%.
- Central Index Key (CIK): 0001582844
Tip: Access up to 7 years of quarterly data
Positions held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 28 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ocular Therapeutix (OCUL) | 14.1 | $14M | +14% | 1.2M | 11.69 |
|
| Cidara Therapeutics Com New (CDTX) | 14.0 | $14M | -21% | 142k | 95.76 |
|
| Tourmaline Bio (TRML) | 13.3 | $13M | -5% | 269k | 47.83 |
|
| Aadi Bioscience (WHWK) | 6.7 | $6.5M | 3.4M | 1.90 |
|
|
| Insmed Com Par $.01 (INSM) | 5.7 | $5.6M | +4% | 39k | 144.01 |
|
| Bright Minds Biosciences Com New (DRUG) | 5.3 | $5.1M | +75% | 85k | 60.66 |
|
| Argen Se - Sponsored Adr (ARGX) | 4.9 | $4.7M | -4% | 6.4k | 737.56 |
|
| Amylyx Pharmaceuticals (AMLX) | 4.7 | $4.5M | NEW | 333k | 13.59 |
|
| Terns Pharmaceuticals (TERN) | 3.9 | $3.8M | +8% | 503k | 7.51 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 3.4 | $3.3M | -4% | 25k | 131.80 |
|
| Compass Therapeutics (CMPX) | 3.0 | $2.9M | NEW | 840k | 3.50 |
|
| Praxis Precision Medicines I (PRAX) | 2.7 | $2.6M | -32% | 50k | 53.00 |
|
| Surrozen Com New (SRZN) | 2.4 | $2.3M | +4% | 178k | 12.88 |
|
| Ascendis Pha- Sponsored Adr (ASND) | 2.0 | $1.9M | -56% | 9.8k | 198.81 |
|
| Krystal Biotech (KRYS) | 1.9 | $1.9M | NEW | 11k | 176.53 |
|
| Oculis Holding Ordinary Shares (OCS) | 1.8 | $1.8M | -4% | 102k | 17.58 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.5 | $1.5M | -6% | 455k | 3.27 |
|
| Cogent Biosciences (COGT) | 1.5 | $1.5M | NEW | 103k | 14.36 |
|
| Zymeworks Del (ZYME) | 1.4 | $1.4M | -4% | 80k | 17.08 |
|
| Verastem Com New (VSTM) | 1.3 | $1.3M | -4% | 143k | 8.83 |
|
| Dianthus Therapeutics (DNTH) | 1.0 | $984k | NEW | 25k | 39.35 |
|
| United Therapeutics Corporation (UTHR) | 1.0 | $963k | NEW | 2.3k | 419.21 |
|
| Inhibrx Biosciences (INBX) | 0.6 | $552k | NEW | 16k | 33.68 |
|
| Fulcrum Therapeutics (FULC) | 0.5 | $526k | -4% | 57k | 9.20 |
|
| Lb Pharmaceuticals Com Shs | 0.5 | $474k | NEW | 30k | 15.79 |
|
| Revolution Medicines (RVMD) | 0.4 | $393k | -84% | 8.4k | 46.70 |
|
| Unicycive Therapeutics (UNCY) | 0.3 | $262k | -4% | 60k | 4.36 |
|
| Nuvation Bio Inc -cw27 *w Exp 07/07/2027 (NUVB.WS) | 0.0 | $18k | 91k | 0.20 |
|
Past Filings by Acuta Capital Partners
SEC 13F filings are viewable for Acuta Capital Partners going back to 2014
- Acuta Capital Partners 2025 Q3 filed Nov. 14, 2025
- Acuta Capital Partners 2025 Q2 filed Aug. 14, 2025
- Acuta Capital Partners 2025 Q1 filed May 15, 2025
- Acuta Capital Partners 2024 Q4 filed Feb. 14, 2025
- Acuta Capital Partners 2024 Q3 filed Nov. 14, 2024
- Acuta Capital Partners 2024 Q2 filed Aug. 14, 2024
- Acuta Capital Partners 2024 Q1 filed May 15, 2024
- Acuta Capital Partners 2023 Q4 filed Feb. 14, 2024
- Acuta Capital Partners 2023 Q3 filed Nov. 14, 2023
- Acuta Capital Partners 2023 Q2 filed Aug. 14, 2023
- Acuta Capital Partners 2023 Q1 filed May 15, 2023
- Acuta Capital Partners 2022 Q4 filed Feb. 14, 2023
- Acuta Capital Partners 2022 Q3 filed Nov. 14, 2022
- Acuta Capital Partners 2022 Q2 filed Aug. 15, 2022
- Acuta Capital Partners 2022 Q1 filed May 16, 2022
- Acuta Capital Partners 2021 Q4 filed Feb. 14, 2022